Press Release Details
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
Kiniksa intends to use the net proceeds from the public offering and the concurrent private placement to advance the clinical development of its product candidates, to fund other research and development activities and for working capital and general corporate purposes.
Kiniksa has filed a registration statement (including a prospectus) with the
A final prospectus supplement related to the public offering (including the accompanying prospectus) will be filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological signaling pathways that are implicated across a spectrum of diseases.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the public offering and the concurrent private placement and our intended use of any net proceeds from the public offering and concurrent private placement.
These forward-looking statements are based on management’s current plans, estimates or expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, risks and uncertainties related to global economic or market conditions, volatility in the share price of our Class A common shares, changes in our operating plan or funding requirements and satisfaction of customary closing conditions.
These and other important factors discussed under the caption “Risk Factors” in our Form 10-Q for the three months ended
|Every Second Counts!™
Kiniksa Investor and Media Contact
Source: Kiniksa Pharmaceuticals, Ltd.